Financials in USD. Standardized financial statements.
A compact view of how Kuros Biosciences AG turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $121.36M | $75.56M | $33.56M | $17.99M | $13.81M | $4.04M | $2.56M | $715,000 | $534,000 | $1.06M |
| Revenue Growth? | +60.6% | +125.1% | +86.6% | +30.2% | +242.0% | +57.7% | +258.2% | +33.9% | -49.7% | 0.0% |
| Cost of Revenue? | $16.51M | $13.52M | $5.09M | $7.22M | $3.75M | $2.37M | $2.64M | $3.42M | $3.31M | $3.95M |
| Gross Profit? | $104.84M | $62.03M | $28.47M | $10.77M | $10.07M | $1.67M | -$79,000 | -$2.70M | -$2.77M | -$2.89M |
| Gross Margin? | +86.4% | +82.1% | +84.8% | +59.9% | +72.9% | +41.4% | -3.1% | -377.8% | -518.9% | -272.5% |
| Operating Expenses? | $97.51M | $67.03M | $41.66M | $24.21M | $18.83M | $13.35M | $11.31M | $11.03M | $11.28M | $22.41M |
| Operating Income? | $7.33M | -$5.00M | -$13.19M | -$13.45M | -$8.77M | -$11.68M | -$11.39M | -$13.73M | -$16.24M | -$21.35M |
| EBITDA? | $10.13M | -$561,000 | -$7.49M | -$7.50M | -$5.29M | -$8.58M | -$8.46M | -$11.74M | -$15.10M | -$19.31M |
| Income Before Tax | $4.17M | -$3.35M | -$9.78M | -$15.99M | -$9.55M | -$12.09M | -$11.82M | -$13.81M | -$16.59M | -$20.28M |
| Income Tax Expense | $2.12M | $370,000 | $380,000 | -$1.40M | -$2.01M | -$574,000 | -$571,000 | -$2.12M | -$109,000 | -$533,000 |
| Net Income? | $2.12M | -$3.72M | -$13.73M | -$14.60M | -$7.54M | -$11.52M | -$11.25M | -$11.69M | -$16.48M | -$19.74M |
| EPS? | $0.06 | $-0.10 | $-0.38 | $-0.43 | $-0.23 | $-0.47 | $-0.66 | $-1.14 | $-1.88 | $-3.19 |
| Diluted EPS? | $0.05 | $-0.10 | $-0.38 | $-0.43 | $-0.23 | $-0.47 | $-0.66 | $-1.14 | $-1.88 | $-3.19 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality